Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
14.51
+0.01 (0.07%)
At close: Sep 18, 2026, 4:00 PM EDT
14.60
+0.09 (0.62%)
Pre-market: Sep 21, 2026, 8:23 AM EDT
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Ultragenyx Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $28.05. The average 1-year stock price forecast is 93.31% higher than the current stock price, while the lowest is $18 (+24.05%) and the highest is $40 (+175.67%).
Price Target: $28.05 (+93.31%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 12 | 12 | 12 | 13 | 9 |
| Buy | 5 | 5 | 5 | 5 | 5 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 19 | 19 | 19 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Reiterates $18 → $20 | Hold | Reiterates | $18 → $20 | +37.84% | Sep 18, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $33 | Buy | Maintains | $33 | +127.43% | Sep 18, 2026 |
| Wedbush | Wedbush | Hold Maintains $23 | Hold | Maintains | $23 | +58.51% | Sep 18, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $37 → $39 | Buy | Reiterates | $37 → $39 | +168.78% | Sep 18, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $33 → $39 | Buy | Maintains | $33 → $39 | +168.78% | Sep 18, 2026 |
Financial Forecast
Revenue This Year
762.99M
from 673.00M
Increased by 13.37%
Revenue Next Year
1.00B
from 762.99M
Increased by 31.21%
EPS This Year
-3.87
from -5.83
EPS Next Year
0.68
from -3.87
EPS and Forward PE are based on non-GAAP adjusted numbers.